And, therefore, it is inappropriate to conclude that “use of GLP-1 agonists for weight loss compared with use of bupropion-naltrexone was associated with increased risk of pancreatitis, gastroparesis, and bowel obstruction but not biliary disease” (1). This evidence concerns the gene GLP1R and intestinal obstruction.